|
GENERAL PEDIATRICS DRUG INFORMATION
Artesunate
Antimalarial
Severe malaria caused by P. falciparum
IV:
Less than 20 kg: 3 mg/kg then repeated in 12, 24, and 48h.
20 kg or more: 2.4 mg/kg then repeated in 12, 24, and 48h.
Patients who meet criteria for severe malaria should receive a minimum of 3 doses before switching to oral follow-on therapy.
CBC to be done q week for 4 weeks following dose to monitor for artesunate associated hemolysis. Accessible through Special Access Program
References: Please refer to criteria from Canadian Malaria Network CMN guidelines 2019.
Updated: 12/21/2022
Disclaimer: This document has been created specifically for Hamilton Health Sciences (HHS) to use for its own patients and the information contained herein may not be applicable or relevant to other health care organizations. This document is for informational purposes only and is not intended to be a substitute for medical or clinical advice from a qualified health care professional. HHS makes no representations or warranties as to the accuracy of the information. This material is current only to the date listed. This material is the intellectual property of HHS and may not be shared, duplicated, or distributed further without the consent of HHS. HHS assumes no liability for the use of this information by the recipient.
| |